Dr Thomas Bachelot
- Specialty
- Oncologist, breast and gynecology expert
- Title
- Assistant department coordinator
- Hospital
- Centre Léon Bérard (Lyon)
- Latest articles
-
- Copy number alterations in metastatic and early breast tumours: prognostic and acquired biomarkers of resistance to CDK4/6 inhibitors. (1 oct. 2024)
- Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. (1 août 2024)
- Association between endocrine adjuvant therapy intake timing and disease-free survival in patients with high-risk early breast cancer: results of a sub-study of the UCBG- UNIRAD trial. (1 juin 2024)
- Trastuzumab deruxtecan in previously treated HER2-positive metastatic or unresectable breast cancer: Real-life data from the temporary use authorization program in France. (1 mai 2024)
- Tucatinib Combination Treatment After Trastuzumab-Deruxtecan in Patients With ERBB2-Positive Metastatic Breast Cancer. (1 avr. 2024)